mAbs N-glycosylation: Implications for biotechnology and analytics

Ting Wang; Li Liu; Josef Voglmeir

doi:10.1016/j.carres.2022.108541

mAbs N-glycosylation: Implications for biotechnology and analytics

Carbohydr Res. 2022 Apr:514:108541. doi: 10.1016/j.carres.2022.108541. Epub 2022 Mar 17.

Authors

Ting Wang¹, Li Liu², Josef Voglmeir³

Affiliations

¹ Glycomics and Glycan Bioengineering Research Center GGBRC, College of Food Science and Technology, Nanjing Agricultural University, China.
² Glycomics and Glycan Bioengineering Research Center GGBRC, College of Food Science and Technology, Nanjing Agricultural University, China. Electronic address: lichen.liu@njau.edu.cn.
³ Glycomics and Glycan Bioengineering Research Center GGBRC, College of Food Science and Technology, Nanjing Agricultural University, China. Electronic address: josef.voglmeir@njau.edu.cn.

PMID: 35344785
DOI: 10.1016/j.carres.2022.108541

Abstract

Monoclonal antibodies (mAbs) are amazingly successful in treating diseases such as various types of cancers, immune disorders, and infections. Currently, mAbs are considered the most versatile therapeutic available. Seminal scientific progress over the last decade on elucidating the functional role of antibody N-glycosylation revealed the significance of this post-translational modification on the stability, half-life, and biological activity of antibodies. Therefore, antibody N-glycosylation became a key aspect of biopharmaceutical mAb production in large-scale manufacturing processes. This Mini-Review summarizes the recent scientific attempts of producing mAbs in glycoengineered animal-, plant-, and yeast cell lines. Furthermore, we also describe novel approaches for analyzing mAb N-glycosylation.

Keywords: Glycoengineering; N-glycosylation; Structural N-Glycan analysis; mAB glycosylation.

Publication types

Review

MeSH terms

Animals
Antibodies, Monoclonal*
Biotechnology
Glycosylation
Neoplasms* / drug therapy
Protein Processing, Post-Translational

Substances

Antibodies, Monoclonal